Swiss National Bank Buys 8,900 Shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)
Swiss National Bank Buys 8,900 Shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)
Swiss National Bank raised its stake in shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA – Get Rating) by 7.2% in the first quarter, according to the company in its most recent disclosure with the SEC. The firm owned 131,700 shares of the biopharmaceutical company's stock after acquiring an additional 8,900 shares during the quarter. Swiss National Bank owned approximately 0.23% of Vanda Pharmaceuticals worth $1,490,000 as of its most recent filing with the SEC.
據萬達製藥最近向美國證券交易委員會披露的信息,瑞士國家銀行在今年第一季度將其在萬達製藥的持股比例提高了7.2%。該公司在本季度增持了8900股後,持有這家生物製藥公司的13.17萬股股票。截至最近提交給美國證券交易委員會的文件,瑞士國家銀行持有萬達製藥約0.23%的股份,價值1,490,000美元。
Other large investors have also made changes to their positions in the company. Qube Research & Technologies Ltd boosted its position in Vanda Pharmaceuticals by 9.0% in the first quarter. Qube Research & Technologies Ltd now owns 88,076 shares of the biopharmaceutical company's stock valued at $996,000 after buying an additional 7,297 shares in the last quarter. Fisher Asset Management LLC grew its stake in shares of Vanda Pharmaceuticals by 74.8% during the first quarter. Fisher Asset Management LLC now owns 69,588 shares of the biopharmaceutical company's stock valued at $787,000 after purchasing an additional 29,786 shares during the last quarter. Royce & Associates LP grew its stake in shares of Vanda Pharmaceuticals by 99.2% during the first quarter. Royce & Associates LP now owns 239,627 shares of the biopharmaceutical company's stock valued at $2,710,000 after purchasing an additional 119,329 shares during the last quarter. SG Americas Securities LLC increased its holdings in shares of Vanda Pharmaceuticals by 11.6% in the first quarter. SG Americas Securities LLC now owns 104,944 shares of the biopharmaceutical company's stock valued at $1,187,000 after purchasing an additional 10,919 shares in the last quarter. Finally, Nisa Investment Advisors LLC lifted its holdings in Vanda Pharmaceuticals by 134.6% during the 1st quarter. Nisa Investment Advisors LLC now owns 8,540 shares of the biopharmaceutical company's stock worth $97,000 after buying an additional 4,900 shares in the last quarter. Institutional investors own 99.42% of the company's stock.
其他大型投資者也改變了他們在該公司的頭寸。Qube Research&Technologies Ltd在第一季度將其在萬達製藥的頭寸提高了9.0%。Qube Research&Technologies Ltd現在擁有這家生物製藥公司88,076股票,價值996,000美元,上個季度又購買了7,297股票。Fisher Asset Management LLC在第一季度增持了74.8%的萬達製藥股份。Fisher Asset Management LLC現在擁有69,588股這家生物製藥公司的股票,價值78.7萬美元,此前在上個季度又購買了29,786股。Royce&Associates LP在第一季度增持了99.2%的Vanda PharmPharmticals股票。Royce&Associates LP現在擁有239,627股這家生物製藥公司的股票,價值2,710,000美元,在上個季度購買了119,329股。SG America Securities LLC在第一季度增持了11.6%的Vanda PharmPharmticals股票。SG America Securities LLC現在擁有這家生物製藥公司104,944股股票,價值1,187,000美元,上個季度又購買了10,919股。最後,NISA Investment Advisors LLC在第一季度增持了134.6%的萬達製藥股份。NISA Investment Advisors LLC現在持有這家生物製藥公司8,540股股票,價值97,000美元,上個季度又購買了4,900股。機構投資者持有該公司99.42%的股票。
Analysts Set New Price Targets
分析師設定新的價格目標
Separately, StockNews.com upgraded Vanda Pharmaceuticals from a "hold" rating to a "buy" rating in a research report on Friday, June 3rd.
另外,在6月3日週五的一份研究報告中,StockNews.com將萬達製藥的評級從持有上調至買入。
Insider Activity at Vanda Pharmaceuticals
萬達製藥的內幕活動
Vanda Pharmaceuticals Trading Down 4.0 %
萬達製藥股價下跌4.0%
Shares of NASDAQ VNDA opened at $10.38 on Friday. The firm has a market capitalization of $587.10 million, a PE ratio of 54.05 and a beta of 0.47. The firm's 50-day moving average is $10.83 and its 200-day moving average is $10.89. Vanda Pharmaceuticals Inc. has a 1 year low of $9.24 and a 1 year high of $21.44.
上週五,納斯達克VNDA的股價開盤報10.38美元。該公司市值為5.871億美元,市盈率為54.05倍,貝塔係數為0.47。該公司的50日移動均線切入位在10.83美元,200日移動均線切入位在10.89美元。Vanda PharmPharmticals Inc.的一年低點為9.24美元,一年高位為21.44美元。
Vanda Pharmaceuticals Profile
萬達製藥簡介
(Get Rating)
(獲取評級)
Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.
萬達製藥公司是一家生物製藥公司,專注於療法的開發和商業化,以滿足高度未得到滿足的醫療需求。該公司的營銷產品包括用於治療非24小時睡眠-覺醒障礙的Hetlioz;以及用於治療精神分裂症的Fanapt口服藥片。
Featured Stories
專題報道
- Get a free copy of the StockNews.com research report on Vanda Pharmaceuticals (VNDA)
- Could Snap Stock Rebound As Management Restructures?
- MarketBeat: Week in Review 8/29 – 9/2
- Hormel Looks Cheap At These Levels
- Lululemon Set To Soar Into September
- Could Nike Stock be Oversold, but Still Overvalued?
- 免費獲取StockNews.com關於萬達製藥的研究報告(VNDA)
- 隨着管理層重組,股市能否迅速反彈?
- MarketBeat:回顧中的一週8/29-9/2
- 霍梅爾在這些水平上看起來很便宜
- 露露檸檬將飆升至9月
- 耐克股票會被超賣,但仍被高估嗎?
Receive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
獲得《Vanda PharmPharmticals Daily》新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對Vanda PharmPharmticals和相關公司的最新新聞和分析師評級的每日簡要摘要。